Introduction {#Sec1}
============

The United Nations has declared that the global burden of chronic non-communicable diseases (NCDs) constitutes one of the major challenges for development in the 21^st^ century, particularly for developing countries. Diabetes mellitus (diabetes) along with cancer, cardiovascular and chronic respiratory diseases represent about 80% of the NCD mortality \[[@CR1]\]. Additionally, diabetes is one of the 10 main causes of global disease burden when evaluated by years of life lived with disability \[[@CR2]\].

The prevalence of diabetes has risen dramatically in the last decades. The International Diabetes Federation (IDF) estimated that 382 million people in 2013 had diabetes, 175 million (46%) being undiagnosed \[[@CR3]\]. Based on the IDF estimates, 80% of the cases of diabetes globally live in low and middle income countries. In absolute numbers, Brazil was ranked 4^th^ among all nations. Yet, prevalence of diabetes in Brazil has been largely based on self-reported cases, given the difficulties in conducting large surveys with laboratory determinations.

The only Brazilian study which included blood glucose measurement and was not based in just one local setting, conducted between 1986 and 1988, found a prevalence of 7.6% in adults 30-69 years of age of various capitals of different geographic regions \[[@CR4]\]. This prevalence certainly underestimates current rates given the epidemiologic and nutritional transitions that have occurred in Brazil over the last decades \[[@CR5]\]. Estimates for impaired glucose tolerance (IGT) \[[@CR3]\] and other categories of risk based on fasting glucose (impaired fasting glucose, IFG) or glycated hemoglobin (elevated HbA~1C~) \[[@CR6]\], frequently referred to as intermediate hyperglycemia or prediabetes, are also either outdated or restricted to local settings.

Thus, to gain insight in terms of the current burden of diabetes and intermediate hyperglycemia with a full accounting of diagnostic laboratory exams (fasting glucose, a 75 g oral glucose tolerance test and a measurement of HbA~1C~), the objective of this study is to describe their prevalence, overall and according to sociodemographic and nutritional variables, in the baseline examination of a large cohort of Brazilian adults conducted in six capitals of Brazil, thus allowing for a broad representation of major relevant population groups.

Methods {#Sec2}
=======

The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) is a prospective cohort study designed to investigate diabetes, cardiovascular and other related chronic diseases, as previously described \[[@CR7], [@CR8]\]. The ethics committee of all institutions approved the research protocol, and all participants gave written consent.

Active or retired civil servants (35-74 years) of universities or research institutions from six state capitals of three different regions of Brazil were invited to participate, totalizing, in 2008, 52,137 potential volunteers. Men, the elderly, and those whose activities did not require a higher education were especially encouraged to participate. A total of 16,435 expressed interest, 15,821 being pre-enrolled. Between 2008 and 2010, 15,105 subjects completed the baseline examination. After excluding three participants who lacked laboratory values, our final sample for analyses comprises 15,102 participants.

A previously validated, comprehensive set of questionnaires, clinical measurements and laboratory tests was carried out. Sociodemographic factors and past medical history were ascertained by questionnaire. Participants were requested to bring their medications or prescriptions to the clinic. Weight and height were measured using standard equipment and techniques. A 12-hour fasting blood sample was drawn in the morning soon after arrival at the research clinic, following standardized procedures for samples collection and processing \[[@CR9]\]. A standardized 75 g oral glucose tolerance test (OGTT) was performed in all participants without known diabetes utilizing an anhydrous glucose solution \[[@CR10]\]. Plasma glucose was measured by the hexokinase method (ADVIA Chemistry; Siemens, Deerfield, Illinois). HbA~1C~ was measured by high-pressure liquid chromatography (Bio-Rad Laboratories, Hercules, California), using a method certified by the National Glycohemoglobin Standardization Program.

Diabetes status was defined in a comprehensive fashion, as follows. A previously diagnosed diabetes was classified when answering, "yes" to either "Have you been previously told by a physician that you had/have diabetes (sugar in the blood)?" or "Have you used medication for diabetes in the past 2 weeks?" Previously undiagnosed diabetes was classified based on laboratory values when reaching the threshold for fasting plasma glucose (FPG; ≥7.0 mmol/L), 2-hour plasma glucose during the OGTT (2 h PG ≥11.1 mmol/L), or HbA~1C~ (≥6.5%; ≥47.5 mmol/mol) \[[@CR11]--[@CR13]\].

More restrictive secondary definitions were also calculated: first, by excluding those classified only on the basis of their HbA~1C~ value, since this test has only recently been recommended for diagnostic purposes; second, by only considering FPG, as this is the approach most frequently used in clinical practice; and finally by also requiring that the participant's report of a previous diagnosis be coupled with either medication use or laboratory confirmation.

Intermediate hyperglycemic states, among those not meeting the comprehensive diabetes definition, used the following cut-offs: impaired glucose tolerance (IGT), a 2 h PG ≥7.8 mmol/L; impaired fasting glucose (IFG; by the World Health Organization -- WHO -- criteria), a FPG ≥6.1 mmol/L \[[@CR13]\], or alternatively a FPG ≥5.6 mmol/L, according to the American Diabetes Association \[[@CR11]\]; and elevated HbA~1C,~ a value ≥5.7% (≥38.8 mmol) \[[@CR11]\] or, alternatively ≥6.0% (≥42.1 mmol) \[[@CR14]\].

Race was defined by the participant's self-declared skin color/race. Educational level was ascertained in years and then classified in levels. Body mass index (BMI) was defined as weight (kg)/height (m^2^) and classified according to the standard definition.

We estimated crude and adjusted prevalences and their 95% confidence intervals through logistic regression using the procedure PROC RLOGIST and the predmarg statement in SUDAAN. Smoothing the lines of prevalence across age was performed using a spline routine (proc gploc; interpol = sm30, SAS). All analyses were done using Statistical Analysis System (SAS 9.3 for Windows software; SAS Institute, Cary, NC) and SUDAAN version 11.0. A p-value of less than 0.05 was considered statistically significant.

Results {#Sec3}
=======

At baseline, mean age was 52.1 years and mean BMI 27.0 kg/m^2^. As seen in Table [1](#Tab1){ref-type="table"}, we enrolled large numbers of men and women, of the four age categories and of participants declaring as being one of the main three race/color categories of the Brazilian population. Of note, 52.6% had a university degree and 63.1% were either overweight or obese.Table 1**Selected socio-demographic and nutritional characteristics of study participants during the baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), 2008-2010**n%95% CI**Gender (n = 15102)** Men688545.644.8-46.4 Women821754.453.6-55.2**Age (n = 15102)** 35-44334022.121.5-22.8 45-54593739.338.5-40.1 55-64423328.027.3-28.8 65-74159210.510.1-11.0**Self-identified skin color/race category (n = 14918)** White778952.251.4-53.0 Black239716.115.5-16.7 Brown ("pardo")420128.227.4-28.9 Asian3742.52.3-2.8 Indigenous1571.10.9-1.2**Educational level (n = 15102)** Incomplete elementary school8945.95.5-6.3 Incomplete secondary school10286.86.4-7.2 Secondary school523234.633.9-35.4 University degree794852.651.8-53.4**Body mass index categories (BMI) (n = 15096)** Underweight (\<18.5 kg/m^2^)1431.00.8-1.1 Normal ( 18.5-24.9 kg/m^2^)542235.935.2-36.7 Overweight (25-29.9 kg/m^2^)607340.239.5-41.0 Obese (≥30 kg/m^2^)345822.922.2-23.6Small differences in total frequency (n) of characteristics are due to missing values.

As shown in Table [2](#Tab2){ref-type="table"}, when utilizing all of the diagnostic information available (definition 1a), the prevalence of diabetes was 19.7% (19.0%-20.3%). By restricting the classification of self-reported diabetes (definition 2a) to cases reporting previous diagnosis combined with either medication use or confirmation by laboratory testing in ELSA, prevalence decreased to 18.4% (17.8%-19.0%). The exclusion of HbA~1C~ from the diagnostic criteria decreased total prevalence by 1.9% for each of the above definitions, to 17.8% (17.2%-18.4%) and to 16.5% (15.9%-17.1%), respectively. When additionally excluding the 2 h post-load plasma glucose, prevalence decreased to 15.1% (14.5%-15.7%) and 13.6% (13.1%-14.2%), respectively. The percentage of previously diagnosed diabetes was generally similar to that of previously undiagnosed diabetes, except when the latter was defined solely by fasting plasma glucose.Table 2**Prevalence of diabetes, baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010**Diabetes definitionsTotal casesCases previously diagnosedCases previously undiagnosedPercent undiagnosed\*n%95% CIn%95% CIn%95% CI%95% CI1. Previously diagnosed (self-report or medication use) *or* undiagnosed reaching: a. diabetes cut-off for HbA~1C~, FPG or 2hPG297019.719.0 -- 20.314739.89.3 -- 10.214979.99.4 -- 10.450.448.6-52.2 b. diabetes cut-off for FPG or 2hPG268817.817.2 -- 18.414739.89.3 -- 10.212158.07.6 -- 8.545.243.3-47.1 c. diabetes cut-off for FPG228015.114.5 -- 15.714739.89.3 -- 10.28075.35.0 -- 5.735.433.4-37.42. Previously diagnosed (restricted definition\*\*) *or* undiagnosed reaching: a. diabetes cut-off for HbA~1C~, FPG or 2hPG277818.417.8 -- 19.012028.07.5 -- 8.4157610.410.0 -- 10.956.754.9-58.6 b. diabetes cut-off for FPG or 2hPG248616.515.9 -- 17.112028.07.5 -- 8.412848.58.1 -- 9.051.749.7-53.6 c. diabetes cut-off for FPG205513.613.1 -- 14.212028.07.5 -- 8.48535.75.3 -- 6.041.539.4-43.6HbA~1C~ = glycated hemoglobin; FPG = fasting plasma glucose; 2hPG = plasma glucose 2 h after a glucose load.\*Cases previously undiagnosed / Total cases.\*\*Requiring that a previous diagnosis of diabetes be accompanied by medication use or be verified by a laboratory result.Diabetes cut offs: FPG (≥7.0 mmol/L); 2-hour PG (≥11.1 mmol/L); or HbA1C (≥6.5%; ≥47.5 mmol/mol).

Frequencies of previously diagnosed and undiagnosed diabetes increased importantly with age among men and women (Table [3](#Tab3){ref-type="table"}). The proportion of those previously undiagnosed (right columns) decreased with increasing age, from 58.3% to 40.6% for the age strata of 35-44 years to 65-74 years.Table 3**Distribution of diabetes cases\* according to categories of sex and age, baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010**Previously diagnosedPreviously undiagnosedPercent undiagnosedMenWomenTotalMenWomenTotalMenWomenTotalAge Stratan%n%%n%n%%%%%35-44603.8392.23.0905.8512.94.260.456.958.345-542368.82026.27.431611.82517.79.657.355.456.555-6431517.028912.214.329115.727011.413.348.048.348.265-7416921.516320.320.912616.010212.714.342.738.540.6**Total**78011.36938.49.882312.06748.29.951.549.450.4\*considering a self-reported diagnosis, use of medication, or a full accounting of glucose abnormalities (Definition 1a in Table [1](#Tab1){ref-type="table"}).

As seen in Table [4](#Tab4){ref-type="table"}, the crude prevalence of total and previously diagnosed diabetes was higher among men and increased markedly with age and with increasing BMI. Whites had a lower prevalence of diabetes than other groups. Highest rates were seen in Asian, black and indigenous Brazilians. A smooth gradient was seen in terms of educational attainment, with participants with lesser education having a notably greater prevalence. Adjustment for the above-mentioned variables resulted in the following comparisons: Among the obese the adjusted prevalence was 2.7 times that among the lean; those over 65 had 4.4 times the adjusted prevalence of those under 45; men had a 42.6% greater prevalence than women; blacks a 37.9% and Asians (primarily of Japanese origin) a 61.0% greater adjusted prevalence than whites; and those not completing elementary school a 64.6% greater adjusted prevalence than those with a university education. Prevalence among "browns", a group with ethnically mixed -- Caucasian, African and to a lesser extent indigenous -- ancestry, was intermediate between that seen among whites and blacks. Although a generally similar pattern was seen when considering only those previously diagnosed diabetes, differences were accentuated across age and BMI categories; Asian, rather than indigenous Brazilians had the highest adjusted frequency among race/color groups.Table 4**Prevalence of total and previously diagnosed diabetes\* according to selected socio-demographic and nutritional characteristics, baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 14912, 2008-2010**Total diabetesPreviously diagnosed diabetesUnadjustedAdjusted\*\*UnadjustedAdjusted\*\*Population correlaten%95% CI%95% CIP valuen%95% CI%95% CIP value**Sex**\<0.0001\<0.0001 Men157223.222.2-24.223.422.5-24.476211.210.5-12.011.410.7-12.2 Women135016.615.8-17.416.415.6-17.26838.47.8-9.08.37.7-8.9**Age (years)**\<0.0001\<0.0001 35-442407.26.4-8.17.97.0-8.9993.02.4-3.63.22.7-3.9 45-5499316.916.0-17.916.515.6-17.44327.46.7-8.07.16.5-7.8 55-64114227.426.1-28.827.025.7-28.359214.213.2-15.314.113.0-15.1 65-7454735.032.7-37.434.632.3-37.032220.618.6-22.620.818.8-22.9**Body mass index (BMI)**\<0.0001\<0.0001 \<25 kg/m^2^59210.89.9-11.611.710.9-12.62684.94.3-5.45.34.8-6.0 25-29.9 kg/m^2^118719.818.8-20.818.918.0-19.960310.19.3-10.89.68.9-10.3 ≥30 kg/m^2^114333.531.9-35.132.130.6-33.657416.815.6-18.116.014.8-17.2**Race/Color**\<0.0001\<0.0001 White129116.615.8-17.417.716.8-18.66348.17.5-8.88.67.9-9.3 Brown83619.918.7-21.119.318.1-20.54069.78.8-10.69.68.7-10.5 Black65527.425.6-29.124.422.7-26.132913.712.4-15.112.311.0-13.6 Indigenous4528.721.5-35.820.915.9-27.02214.08.5-19.59.86.5-14.6 Asian9525.421.0-29.828.524.3-33.15414.410.9-18.015.712.4-19.7**Educational attainment**\<0.0001\<0.0001 Incomplete elementary33137.734.5-40.926.524.0-29.217720.117.5-22.813.211.4-15.3 Incomplete secondary30730.127.3-32.923.421.2-25.815415.112.9-17.311.49.8-13.2 Secondary school112321.720.5-22.822.121.0-23.355510.79.9-11.611.210.3-12.1 University degree116114.814.0-15.616.115.3-17.05597.16.6-7.77.77.1-8.4\*considering self-reported diagnosis, use of medication, and a full accounting of glucose abnormalities (Definition 1a in Table [1](#Tab1){ref-type="table"}).\*\*Adjusted for other variables in table and study center.

As shown in Table [5](#Tab5){ref-type="table"}, prevalence of intermediate hyperglycemia varied considerably according to the definition used. The prevalence of IGT (20.3%) was similar to that of IFG based on the WHO criteria (19.1%). However, the prevalence of IFG based on the ADA criteria was much larger (52.6%). Regardless of the criteria used, these intermediate states of hyperglycemia were higher in men. When classified by HbA~1C~ values, intermediate hyperglycemia was present in 16.1% (ADA definition) and in 7% (using the previous Expert Committee recommendation), and was more common among women.Table 5**Prevalence of intermediate states of hyperglycemia,\* baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010**TotalMen (n = 6885)Women (n = 8217)n%95% CIn%95% CIn%95% CI**IGT**306420.319.7-20.9145521.120.2-22.1160919.618.7-20.4**IFG (WHO)**288619.118.5-19.7168024.423.4-25.4120614.713.9-15.4**IFG (ADA)**794652.651.8-53.4405058.857.7-60.0389647.446.3-48.5**Intermediate HbA** ~**1C**~ **(ADA** ~**)**~ **\*\***243116.115.5-16.7101114.713.9-15.5142017.316.5-18.1**Intermediate HbA** ~**1C**~ **≥6.0%\*\*\***10497.06.5-7.44336.35.7-6.96167.56.9-8.1**IFG (WHO) or IGT**468431.030.3-31.8240635.033.8-36.1227827.726.8-28.7**IFG (ADA) or IGT**847256.155.3-56.9421761.360.1-62.4425551.850.7-52.9**IFG (WHO) or Intermediate HbA** ~**1C**~ **(ADA)**451429.929.2-30.6226632.931.8-34.0224827.426.4-28.3**IFG (ADA) or Intermediate HbA** ~**1C**~ **(ADA)**853256.555.7-57.3421061.260.0-62.3432252.651.5-53.7**IGT, IFG (WHO) or Intermediate HbA** ~**1C**~ **(ADA)**592939.338.5-40.0285241.440.3-42.6307737.536.4-38.5**IGT, IFG (ADA) or Intermediate HbA** ~**1C**~ **(ADA)**897159.458.6-60.2435663.362.1-64.4461556.255.1-57.2\*After excluding diabetes defined by a self report, medication use or elevated HbA~1C~, fasting plasma glucose or plasma glucose 2 h after a glucose load.\*\*HbA~1C~ ≥5.7% (≥38.8 mmol).\*\*\*HbA~1C~ ≥6.0% (≥42.1 mmol).IGT = impaired glucose tolerance; IFG = impaired fasting glucose; ADA = American Diabetes Association; WHO = World Health Organization; HbA~1C~ = glycated hemoglobin.

Considering that tests are frequently done together in the clinical setting, we also analyzed test results jointly. The frequency of intermediate hyperglycemia reached very high values, varying from 29.9% to 59.4% depending on the definition used (Table [5](#Tab5){ref-type="table"}).

Table [6](#Tab6){ref-type="table"} shows that in both men and women, the frequency of IGT increased by age categories. A similar pattern was observed with IFG defined by the WHO criteria, with the exception of the oldest men. IFG (ADA) decreased by age among men, and did not change much among women over 45 years. Elevated HbA1~C~ increased slightly with age among women, but showed no clear age trend among men. Ethnic differences in the prevalence of intermediate hyperglycemia categorized according to the various definitions were generally small, the exception being for the category defined by HbA~1C~, for which blacks had a considerably greater prevalence.

Considering diabetes and intermediate hyperglycemia together, more than half of participants presented an abnormality, regardless of the criteria used to define IFG. In fact, when IFG (ADA) was considered, this combined frequency reached 79.1%, leaving only 20.9% of participants classified as having normoglycemia. Figure [1](#Fig1){ref-type="fig"} illustrates the fully accounted burden of diabetes and intermediate hyperglycemia graphically, showing the cumulative percentage of participants presenting these conditions by age. Of note, over 80% of participants aged 50 or greater were affected, and this fraction exceeded 90% in those above age 65.Table 6**Distribution of intermediate hyperglycemia categories\* according to sex, race and age, baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010**Impaired glucose toleranceImpaired fasting glucose (WHO)Impaired fasting glucose (ADA)Intermediate HbA ~1C~ \*\*MenWomenTotalMenWomenTotalMenWomenTotalMenWomenTotaln%n%%n%n%%n%n%%n%n%%**Total**145521.1160919.620.3168024.4120614.719.1405058.8389647.452.6101114.7142017.316.1**Age**35-4426316.928616.116.428618.31327.412.597662.567537.949.424015.424413.714.545-5455620.760618.619.668125.447114.419.4163561.0160549.354.642215.757317.616.855-6442823.147720.121.451227.644418.722.6102855.4122251.453.223712.844618.816.165-7420826.424029.928.120125.515919.822.641152.239449.050.611214.215719.516.9**Race/Color (n = 14918)**White80422.382819.821.089524.959714.219.2222661.9203248.554.749813.863915.314.6Brown40520.044020.220.147823.633815.519.4115557.0106048.752.729214.439017.916.2Black17919.025017.217.921522.920914.417.748952.061742.446.118119.233122.721.4Indigenous1920.71015.418.52325.01421.523.65256.53147.752.91010.91116.913.4Asian2922.76626.825.44031.33213.019.36953.911948.450.31511.73514.213.4\*After excluding diabetes defined by self-report, medication use or HbA~1C~, FPG or 2hPG.\*\*HbA~1C~ ≥5.7% (≥38.8 mmol).Figure 1**Percent of the total sample presenting a glucose abnormality by category and age.** Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), N = 15102, 2008-2010. Smoothing performed using a spline routine (Statistical Analysis System). DM = diabetes mellitus; IGT = impaired glucose tolerance; iIFG (WHO) = isolated impaired fasting glucose; iIFG(ADA) represents the additional cases of IFG when ascertained by the ADA criteria; iPre-diabetes by HbA1c represents the additional cases of intermediate hyperglycemia when diagnosed by ADA criteria; WHO = World Health Organization; ADA = American Diabetes Association. See Methods for diagnostic criteria.

Discussion {#Sec4}
==========

The prevalence of diabetes in Brazil assessed by self-reported has increased over the last two decades, in part due to greater access to diagnostic testing \[[@CR5]\]. In the late 1980s, the prevalence was 4.1% in individuals 30-69 years residing in various metropolitan areas \[[@CR4]\]. In 2006, a telephone survey based on wider age range (18 years or older), found a prevalence of 5.3% among adults residing in Brazilian capital cities \[[@CR15]\]. Conducted annually ever since with similar probabilistic samples, this telephone survey found a prevalence of 6.8% by 2012 \[[@CR16]\], a 28% jump in just seven years. Of note, when using comparable diabetes definitions (self-reported diagnosis, without consideration of medication use) and age ranges, the prevalence of known diabetes (8.8%) in our cohort, which is based in six of the 22 cities covered by the annual telephone survey, was quite comparable to that observed (9.8%) in the 2010 telephone survey \[[@CR8]\].

That intermediate degrees of hyperglycemia were extremely common suggests that the prevalence of diabetes will increase for several years to come. For every one adult with diabetes in our sample, approximately one had IGT (20.3%) and 1.5 IGT or IFG (≥6.1 mol/L; 31.0%). If the lower ADA IFG cut point (≥5.6 mol/L) were used, almost 3 adults (56.1%) would be classified as having either IGT or IFG for every one with diabetes. Data from a recent meta-analysis suggest that over a 10 year period, approximately 1 in 3 of those with intermediate hyperglycemia by IFG (ADA) or HbA~1C~ criteria, almost half of those with intermediate hyperglycemia by IFG (WHO) or with IGT, and 70% of those with IFG and IGT will convert to frank diabetes \[[@CR6]\]. The relevance of expanding the WHO definition of IFG to that of the ADA by including fasting glucose in the 100-109 mg/dL range is unclear, and is a major issue, as it labels a very large fraction of the population as being at risk.

Additionally, the disparities in the prevalence of intermediate hyperglycemia when assessed by these different measures and also when assessed by a specific measure in varying age and sex groups suggest that these measures result, to a certain extent, from different processes. Of note in this regard, elevated HbA1c was more common among blacks, which is consistent with previous studies \[[@CR17]\].

The time trend indicated by these Brazilian studies is consistent with findings from around the world which show dramatic increases in diabetes prevalence over the past few decades \[[@CR3], [@CR18]\]. When a similar age group is used for comparison, our rates of diabetes are higher than those recently reported for China and for Panama \[[@CR19], [@CR20]\]. The high prevalences we found for intermediate hyperglycemia are also consistent with those previously reported globally \[[@CR3], [@CR18], [@CR19], [@CR21]\]. The much higher prevalence we found for IFG based on the ADA criteria in comparison with those for other intermediate hyperglycemic states has been previously described \[[@CR22]\].

The burden of diabetes we observed in specific sub-groups is remarkable. A total of 27.5% of those between 55 and 64 years of age had diabetes, this percentage rising to 35.2% for those aged 65 to 74. Of note, this latter percentage of 35.2% reflects an individual's probability of developing diabetes across the lifespan, a probability which is not readily perceived when risk is expressed as mean diabetes prevalence among adults ≥18 years of age, especially when this is based on self-report (e.g. 7.4%). Similarly, 33.7% of all obese participants had diabetes. More than 25% of all blacks, those of Asian descent and indigenous Brazilians, and more than 30% of all those with less than a high school education had diabetes. In fact, with full accounting and using the ADA definition of IFG, only 12.8% of obese participants, and only 10.9% of participants greater than 65 years of age, could be classified as having normoglycemia.

A full understanding of the origins of the global epidemic of diabetes and intermediate hyperglycemia has yet to be assembled. Factors possibly related to it, for example, high sugar consumption, have been little investigated in Brazil. However, regardless of the multitude of possible causes involved, there is no doubt that the obesity epidemic has played a major role. Since the obesity burden in Brazil, as in many settings, is shifting toward the poor \[[@CR23]\], this may explain, in part, the social gradient here described for diabetes prevalence. Of note, the high prevalence we found among Asian descendents is consistent with previous studies \[[@CR24]\].

Meriting discussion also is the proportion of previously undiagnosed diabetes we found, which was similar to that seen in a Brazilian population survey based on results of an OGTT (46%), conducted in the late 1980s \[[@CR4]\]. We expected a lower proportion of undiagnosed diabetes in response to the greater access to health services in recent decades. At least two reasons may explain our findings. First, when our undiagnosed cases were ascertained with all possible diagnostic tests, their contribution to overall prevalence was higher than when ascertained only with fasting glucose, which is still the most common clinical practice. In fact, when only fasting plasma glucose was used to define undiagnosed diabetes, the proportion was lower, only 35.4%. Second, the diagnosis of asymptomatic cases of diabetes in clinical practice requires confirmation on a different day, while our classification of undiagnosed diabetes (as in most epidemiologic surveys) was based on only one examination. Based on published estimates \[[@CR25]\], this, by itself, could reduce the prevalence of undiagnosed diabetes by 25%. Nevertheless, it is clear that the absolute prevalences of both diagnosed and undiagnosed diabetes are in rapid ascension globally \[[@CR3]\], and that most previously undetected cases in our study are likely to represent real cases in the community.

Our study has important strengths, including the size and diversity of the sample studied and the standardized data collection. The capacity to fully account for hyperglycemia and the various means of ascertainment of diabetes and intermediate hyperglycemia permit a comprehensive description of the disease burden across relevant socioeconomic groups, which is rarely accomplished in large surveys, particularly those from low and middle income countries.

Limitations to our study also merit discussion. First, our sample, consisting of university and research institute employees with stable employment and a high educational achievement, is not representative of the entire Brazilian population. However, as already mentioned, in terms of self-reported diabetes prevalence, our findings differ little from those found in a representative sample of similarly aged adults from Brazil's capital cities \[[@CR8]\]. Moreover, since diabetes prevalence is inversely related to educational attainment, if a bias is present in our sample through under-representation of those with less formal education, it is, if anything, likely to be a conservative one, leading to an underestimation of the prevalence of hyperglycemic conditions. Further, since we based our sample on individuals living in metropolitan areas, our results are most readily generalized to urban Brazil, which, according to the 2010 census, is the home of 84% of the Brazilian population \[[@CR26]\].

Second, our ascertainment of previously known diabetes may suffer from the increased diabetes and intermediate hyperglycemia screening in recent years, since participants may tell us, erroneously, that they have diabetes when they have lesser than diabetes hyperglycemia. Further, a positive response to the question about diabetes medication use may also inadvertently ascertain diabetes when in fact the medication was being used to prevent, rather than to treat diabetes. However, though they would upwardly bias our prevalences, the effect of these problems is likely to be small, as shown by the minimal differences in prevalence seen comparing definitions 1 and 2 (Table [2](#Tab2){ref-type="table"}).

Within these limitations, we were able to provide an accurate and full ascertainment of diabetes (previously diagnosed or not) and intermediate hyperglycemia for a diverse population of adults living in several Brazilian capital cities. Specifically, we highlighted a major aggregate burden of these conditions, particularly present in the elderly, in non-whites, in the obese and in those with less schooling. Since diabetes has been estimated to decrease the lifespan of middle-aged individuals by 6 years \[[@CR27]\], these findings lend support to the current discourse of the need to address the challenges of diabetes in the 21^st^ century by allocating greater focus and resources to preventive actions known to be effective \[[@CR1], [@CR28]\].

This burden, which has increased in Brazil and elsewhere in parallel with the climbing rates of obesity and the aging of the population, is truly a public health disaster in slow motion. For low and middle income countries, including Brazil, in which the preventive focus remains largely directed toward infection diseases and problems of maternal and child health, few public health preventive actions are currently as important as that of developing and implementing a strategy to control the rise of obesity and diabetes. Finally, since diabetes is more frequent among the less privileged of society, such actions will additionally contribute to ameliorate health inequities.

In conclusion, with full accounting, the prevalence of diabetes and intermediate hyperglycemia is very high, indicating the necessity of public health and clinical preventive actions.
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